Cytogen, Inc. (KOSDAQ:217330)

Cytogen Statistics

Total Valuation

Cytogen has a market cap or net worth of KRW 64.25 billion. The enterprise value is 44.94 billion.

Market Cap	64.25B
Enterprise Value	44.94B

Important Dates

The next estimated earnings date is Friday, November 21, 2025.

Earnings Date	Nov 21, 2025
Ex-Dividend Date	n/a

Share Statistics

Cytogen has 23.07 million shares outstanding. The number of shares has increased by 11.94% in one year.

Current Share Class	23.07M
Shares Outstanding	23.07M
Shares Change (YoY)	+11.94%
Shares Change (QoQ)	n/a
Owned by Insiders (%)	18.13%
Owned by Institutions (%)	n/a
Float	10.52M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	3.09
PB Ratio	1.49
P/TBV Ratio	2.15
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-2.73
EV / Sales	2.16
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-4.28

Financial Position

The company has a current ratio of 3.30, with a Debt / Equity ratio of 0.36.

Current Ratio	3.30
Quick Ratio	3.02
Debt / Equity	0.36
Debt / EBITDA	n/a
Debt / FCF	-1.47
Interest Coverage	-3.79

Financial Efficiency

Return on equity (ROE) is -33.72% and return on invested capital (ROIC) is -8.24%.

Return on Equity (ROE)	-33.72%
Return on Assets (ROA)	-7.26%
Return on Invested Capital (ROIC)	-8.24%
Return on Capital Employed (ROCE)	-15.20%
Revenue Per Employee	495.33M
Profits Per Employee	-392.64M
Employee Count	42
Asset Turnover	0.29
Inventory Turnover	9.10

Taxes

Income Tax	-980.19M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -60.20% in the last 52 weeks. The beta is -0.21, so Cytogen's price volatility has been lower than the market average.

Beta (5Y)	-0.21
52-Week Price Change	-60.20%
50-Day Moving Average	2,760.30
200-Day Moving Average	3,568.85
Relative Strength Index (RSI)	50.42
Average Volume (20 Days)	533,195

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Cytogen had revenue of KRW 20.80 billion and -16.49 billion in losses. Loss per share was -718.06.

Revenue	20.80B
Gross Profit	5.53B
Operating Income	-8.37B
Pretax Income	-17.47B
Net Income	-16.49B
EBITDA	-5.75B
EBIT	-8.37B
Loss Per Share	-718.06

Balance Sheet

The company has 35.13 billion in cash and 15.41 billion in debt, giving a net cash position of 19.72 billion or 854.71 per share.

Cash & Cash Equivalents	35.13B
Total Debt	15.41B
Net Cash	19.72B
Net Cash Per Share	854.71
Equity (Book Value)	43.24B
Book Value Per Share	1,856.46
Working Capital	30.67B

Cash Flow

In the last 12 months, operating cash flow was -8.54 billion and capital expenditures -1.96 billion, giving a free cash flow of -10.50 billion.

Operating Cash Flow	-8.54B
Capital Expenditures	-1.96B
Free Cash Flow	-10.50B
FCF Per Share	-455.16

Margins

Gross margin is 26.59%, with operating and profit margins of -40.22% and -79.27%.

Gross Margin	26.59%
Operating Margin	-40.22%
Pretax Margin	-83.97%
Profit Margin	-79.27%
EBITDA Margin	-27.66%
EBIT Margin	-40.22%
FCF Margin	n/a

Dividends & Yields

Cytogen does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-11.94%
Shareholder Yield	-11.94%
Earnings Yield	-25.67%
FCF Yield	-16.34%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on September 28, 2022. It was a forward split with a ratio of 3.

Last Split Date	Sep 28, 2022
Split Type	Forward
Split Ratio	3

Scores

Cytogen has an Altman Z-Score of 1.7 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	1.7
Piotroski F-Score	4